Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Indian pharmaceutical companies are not rushing to relocate manufacturing to the United States despite former President Donald Trump's renewed threat of tariffs up to 200 per cent on imported generic drugs. Instead, they are leveraging existing US plants, contract manufacturers, and making selective investments in complex products while maintaining India as their primary production hub.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025. The company, which had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, said its managing director & global CEO, Umang Vohra, has decided not to seek re-appointment upon completion of his current term on March 31, 2026, Cipla Ltd said in a regulatory filing.
As the Indian version of The Archies gets ready to hit OTT, Deepa Gahlot picks 10 interesting college-and-youth-oriented shows on OTT.
